Ikena bags $120M to advance growing pipeline of cancer drugs

Ikena Oncology has raised $120 million to advance its expanding pipeline of cancer drugs. The series B round comes as Ikena prepares to add a TEAD inhibitor to its roster of clinical programs and hustles a first-in-class KRAS asset through lead optimization.